A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with
advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic
nature of tumors. The study is designed to establish the safety including the maximum
tolerated dose, the pharmacokinetics, and the anti-tumor activity of TH-302.